Aigen Investment Management, LP Argenx Se Transaction History

Aigen Investment Management, LP

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2023 Nov 13, 2023	SELL	$369.35 - $548.43 $129,272 - $191,950	-350 Reduced 26.06%	993 $488,000
Q2 2023 Aug 14, 2023	SELL	$360.14 - $422.58 $765,657 - $898,405	-2,126 Reduced 61.29%	1,343 $523,000
Q1 2023 May 15, 2023	SELL	$334.23 - $403.65 $668,460 - $807,300	-2,000 Reduced 36.57%	3,469 $1.29 Million
Q4 2022 Feb 10, 2023	SELL	$342.17 - $402.31 $39,691 - $46,667	-116 Reduced 2.08%	5,469 $2.07 Million
Q3 2022 Nov 09, 2022	BUY	$343.2 - $395.75 $1.92 Million - $2.21 Million	5,585 New	5,585 $1.97 Million
Q2 2020 Aug 10, 2020	SELL	$127.44 - $232.72 $1.28 Million - $2.34 Million	-10,071 Closed	0 $0
Q1 2020 May 08, 2020	BUY	$108.83 - $165.23 $1.1 Million - $1.66 Million	10,071 New	10,071 $1.33 Million

400

30.9M

376K

489K

Ticker ARGX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 55,323,800
Market Cap $34.9B
Description
argenx SE, a biotechnology company, focuses on developing various therapies for the treatment of autoimmune diseases in the United States, the Netherlands, Belgium, Japan, Switzerland, Germany and France. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, ...

Get notified when there are updates to the investment portfolio of Aigen Investment Management, LP, based on Form 13F filings with the SEC.

Stay updated on Aigen Investment Management, LP with notifications on news.